MX2023012368A - Vacuna de virus. - Google Patents
Vacuna de virus.Info
- Publication number
- MX2023012368A MX2023012368A MX2023012368A MX2023012368A MX2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A MX 2023012368 A MX2023012368 A MX 2023012368A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- infection
- agents
- amino acid
- disclosure relates
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 5
- 229960005486 vaccine Drugs 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 4
- 230000009385 viral infection Effects 0.000 abstract 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 208000001528 Coronaviridae Infections Diseases 0.000 abstract 1
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000005875 antibody response Effects 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se relaciona con el campo de la prevención o el tratamiento de infecciones virales. En particular, la divulgación se refiere a agentes para la vacunación contra la infección viral y a la inducción de respuestas inmunitarias específicas de antígenos virales eficaces, tales como respuestas de anticuerpos y/o células T, y métodos para generar y utilizar dichos agentes. La administración de agentes tales como el ARN descrito en el presente documento a un sujeto puede proteger al sujeto contra la infección por virus. Específicamente, la presente divulgación se refiere a secuencias de aminoácidos que comprenden al menos una porción de una proteína viral que tiene modificaciones de aminoácidos encontradas en otras variantes de la proteína viral. Administración de ARN que codifica una o más de las secuencias de aminoácidos pueden proporcionar protección contra diversas variantes del virus. Los métodos y agentes descritos en el presente documento son, en particular, útiles para la prevención o el tratamiento de la infección por coronavirus tal como la infección por SARS-CoV-2.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2021060273 | 2021-04-20 | ||
| PCT/EP2022/060417 WO2022223617A1 (en) | 2021-04-20 | 2022-04-20 | Virus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012368A true MX2023012368A (es) | 2023-11-01 |
Family
ID=81579467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012368A MX2023012368A (es) | 2021-04-20 | 2022-04-20 | Vacuna de virus. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240383947A1 (es) |
| EP (1) | EP4326317A1 (es) |
| JP (1) | JP2024517642A (es) |
| KR (1) | KR20240009419A (es) |
| CN (1) | CN117750974A (es) |
| AU (1) | AU2022260466A1 (es) |
| BR (1) | BR112023021654A2 (es) |
| CA (1) | CA3215771A1 (es) |
| IL (1) | IL307762A (es) |
| MX (1) | MX2023012368A (es) |
| WO (1) | WO2022223617A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| CN117153245B (zh) * | 2023-10-18 | 2024-03-19 | 无锡市疾病预防控制中心 | 预测新型冠状病毒S蛋白RBD区域与hACE2受体相互作用的方法 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US20050287153A1 (en) | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
| US7176278B2 (en) | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
| ES2655912T3 (es) | 2002-11-08 | 2018-02-22 | Ablynx N.V. | Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos |
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| CN101646689A (zh) | 2006-09-08 | 2010-02-10 | 埃博灵克斯股份有限公司 | 具有长半衰期的血清清蛋白结合蛋白 |
| BRPI0821924A2 (pt) | 2007-12-27 | 2015-07-07 | Novartis Ag | Moléculas de ligação baseadas em fibronectina melhoradas e seu uso |
| JP6192891B2 (ja) | 2008-05-02 | 2017-09-06 | ノバルティス アーゲー | 改善されたフィブロネクチンベースの結合分子およびそれらの使用 |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| CA2779073C (en) | 2009-10-30 | 2017-10-24 | Domain Therapeutics | Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| CN106977608A (zh) | 2010-04-09 | 2017-07-25 | 阿尔布麦狄克斯公司 | 白蛋白衍生物和变体 |
| MX2012011781A (es) | 2010-04-13 | 2012-11-16 | Squibb Bristol Myers Co | Proteinas de dominio de armazon basadas en fibronectina que se unen a la proteina convertasa subtilisina kexina tipo q (pcsk9). |
| EP2758436B1 (en) | 2011-09-23 | 2019-06-12 | Universität Stuttgart | Serum half-life extension using immunoglobulin binding domains |
| WO2013075066A2 (en) | 2011-11-18 | 2013-05-23 | Eleven Biotherapeutics, Inc. | Proteins with improved half-life and other properties |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
-
2022
- 2022-04-20 AU AU2022260466A patent/AU2022260466A1/en active Pending
- 2022-04-20 EP EP22720733.9A patent/EP4326317A1/en active Pending
- 2022-04-20 CA CA3215771A patent/CA3215771A1/en active Pending
- 2022-04-20 CN CN202280043287.9A patent/CN117750974A/zh active Pending
- 2022-04-20 US US18/287,608 patent/US20240383947A1/en active Pending
- 2022-04-20 WO PCT/EP2022/060417 patent/WO2022223617A1/en not_active Ceased
- 2022-04-20 KR KR1020237039881A patent/KR20240009419A/ko active Pending
- 2022-04-20 MX MX2023012368A patent/MX2023012368A/es unknown
- 2022-04-20 JP JP2023564119A patent/JP2024517642A/ja active Pending
- 2022-04-20 BR BR112023021654A patent/BR112023021654A2/pt not_active Application Discontinuation
- 2022-04-20 IL IL307762A patent/IL307762A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112023021654A2 (pt) | 2023-12-26 |
| JP2024517642A (ja) | 2024-04-23 |
| CA3215771A1 (en) | 2022-10-27 |
| EP4326317A1 (en) | 2024-02-28 |
| US20240383947A1 (en) | 2024-11-21 |
| IL307762A (en) | 2023-12-01 |
| WO2022223617A1 (en) | 2022-10-27 |
| AU2022260466A1 (en) | 2023-11-02 |
| CN117750974A (zh) | 2024-03-22 |
| KR20240009419A (ko) | 2024-01-22 |
| AU2022260466A9 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000411A (es) | Vacuna combinada de sars-cov-2 e influenza. | |
| MX2023012368A (es) | Vacuna de virus. | |
| MX2024009072A (es) | Vacuna contra el coronavirus. | |
| MX2022015132A (es) | Vacunas combinadas a base de acidos nucleicos. | |
| MX2022009688A (es) | Composición y métodos de vacunas de arnm contra la nueva infección por coronavirus. | |
| EP4226938A3 (en) | Coronavirus vaccine | |
| WO2005116270A3 (en) | Influenza virus vaccine composition and method of use | |
| WO2023147092A3 (en) | Coronavirus vaccine | |
| DE60324678D1 (de) | N t-lymphozyten und damit identifizierte hsv-antigene | |
| PH12022552249A1 (en) | Vaccines against coronavirus and methods of use | |
| NO20021479D0 (no) | Immunologiske signifikante herpes simplex virus antigener og metoder for å identifisere og å bruke dem | |
| PH12022552084A1 (en) | Vaccine against african swine fever virus infection | |
| MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
| WO2022197720A3 (en) | Compositions and methods for treating coronavirus infection | |
| WO2003011893A3 (en) | Immunologically significant herpes simplex virus antigens and methods for using same | |
| NO20052136L (no) | Vaksine mot Hepatitt C-virus (HCV). | |
| EP4295862A3 (en) | Coronavirus vaccine | |
| EP1471936A4 (en) | HIV VACCINE AND METHOD OF USE | |
| MX2023003784A (es) | Peptido derivado de proteina de sars-cov-2 y vacuna que lo contiene. | |
| MX2023003377A (es) | Compuesto para aumentar la eficacia de los vectores virales. | |
| UY40490A (es) | Vacunas de combinación para prevenir y/o tratar múltiples agentes infecciosos | |
| WO2022010813A3 (en) | Enhancing immune responses through targeted antigen expression | |
| MXPA02005506A (es) | Clonacion de un gen que codifica una racemasa de aminoacido derivada de tripanosoma cruzi, y usos del mismo. | |
| DE602007010127D1 (en) | Hiv-impfstoff | |
| ZA202309368B (en) | Lentiviral vector, lentiviral particle for treating hepatitis b and its preparation method and application thereof |